KAWASAKI, Japan – March 30, 2021 – Jiksak Bioengineering, Inc. (Jiksak), a biotechnology company focused on finding a cure for amyotrophic lateral sclerosis (ALS), and Sharp Display Technology Corp. (SDTC) today announced that they have successfully obtained electrophysiological data from their co-developed nerve organoid device.
This device combines Jiksak’s unique Nerve Organoid with SDTC’s sensitive electrode chip, enabling non-invasive quantitative measurement of neuron firing. The novel technology is expected to speed up drug discovery and help elucidate neural disease pathology. Jiksak aims to begin sales of the device as soon as possible.
Jiksak Bioengineering, Inc. is a biotechnology company based in Kawasaki, Japan, which focuses on finding a cure for neurodegenerative and neuromuscular diseases, especially amyotrophic lateral sclerosis (ALS). Founded in 2017, the company has developed both synapse induction technology and a unique iPS cell-derived neural tissue analysis organoid. Jiksak’s platform provides an efficient method to actively drive drug discovery and toxicity testing.
For more information, please visit www.jiksak.co.jp/